Literature DB >> 20622675

Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine.

Athena P Kourtis1, Sascha Ellington, Pooja Bansil, Denise J Jamieson, Samuel F Posner.   

Abstract

We describe hospitalization trends of invasive pneumococcal disease (IPD) among HIV-infected adolescents and adults since the introduction of highly active antiretroviral therapy (HAART) and the 7-valent pneumococcal conjugate vaccine (PCV7) in the United States, using the nation-wide inpatient sample. We estimated national trends of IPD hospitalizations during 3 periods: 1994-1995 (pre-HAART/pre-PCV7); 1998-1999 (HAART/pre-PCV7); and 2004-2005 (HAART/ early PCV7). The number of IPD hospitalizations among HIV-infected individuals declined 49.2% between 1994/1995 and 2004/2005. Compared with 1994-1995, the adjusted odds ratio for IPD hospitalizations of HIV-infected adolescents and adults in the United States during 2004-2005 was 0.64 (95% confidence interval: 0.54 to 0.77). The decrease was observed after introduction of the PCV7.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20622675     DOI: 10.1097/QAI.0b013e3181e8ed15

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  [Vaccination against pneumococci and influenza. How good is the evidence?].

Authors:  B Babouee; A F Widmer; M Battegay
Journal:  Internist (Berl)       Date:  2011-03       Impact factor: 0.743

3.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

4.  Trends in Diagnoses Among Hospitalizations of HIV-infected Children and Adolescents in the United States: 2003-2012.

Authors:  Stacey A Hurst; Alexander C Ewing; Sascha R Ellington; Athena P Kourtis
Journal:  Pediatr Infect Dis J       Date:  2017-10       Impact factor: 2.129

Review 5.  Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Authors:  Kuan-Yeh Lee; Mao-Song Tsai; Kuang-Che Kuo; Jen-Chih Tsai; Hsin-Yun Sun; Aristine C Cheng; Sui-Yuan Chang; Chen-Hsiang Lee; Chien-Ching Hung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program.

Authors:  Marta C Nunes; Anne von Gottberg; Linda de Gouveia; Cheryl Cohen; Locadiah Kuwanda; Alan S Karstaedt; Keith P Klugman; Shabir A Madhi
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

7.  Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.

Authors:  Francesca Lombardi; Simone Belmonti; Massimiliano Fabbiani; Matteo Morandi; Barbara Rossetti; Giacinta Tordini; Roberto Cauda; Andrea De Luca; Simona Di Giambenedetto; Francesca Montagnani
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.